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Introduction: In the relapsed setting, arsenic trioxide remains the backbone of treatment. Scant literature exists
regarding treatment of relapsed acute promyelocytic leukemia in patients with renal failure. To the best of our
knowledge we are the first to report a safe and effective means of treatment for relapsed acute promyelocytic
leukemia in the setting of advanced renal failure, employing titration of arsenic trioxide based on clinical
parameters rather than arsenic trioxide levels.
Case presentation: A 33-year-old Caucasian man with a history of acute promyelocytic leukemia in remission for
3 years, as well as dialysis-dependent chronic renal failure secondary to a solitary kidney and focal segmental
glomerulosclerosis and human immunodeficiency virus infection, receiving highly active antiretroviral therapy
presented to our hospital with bone marrow biopsy-confirmed relapsed acute promyelocytic leukemia. Arsenic
trioxide was begun at a low dose with dose escalation based only on side effect profile monitoring and not
laboratory testing for induction as well as maintenance without undue toxicity. Our patient achieved and remains
in complete hematologic and molecular remission as of this writing.
Conclusion: Arsenic trioxide can be used safely and effectively to treat acute promyelocytic leukemia in patients
with advanced renal failure using careful monitoring of side effects rather than blood levels of arsenic to guide
therapeutic dosing.Introduction
Arsenic trioxide has been used as a treatment for
leukemia since the late 1800s [1]. Since that time add-
itional studies have been reported examining the efficacy
of arsenic trioxide in relapsed acute promyelocytic
leukemia (APL) [2-5], but little has been published con-
cerning the use of this agent in patients with renal fail-
ure. Only one case report has been published reporting
on the dosing, effectiveness and tolerability of arsenic
trioxide therapy in a patient requiring temporary
hemodialysis [6]. We report a case of a patient with end-
stage chronic renal failure on daily home hemodialysis
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reproduction in any medium, provided the orfor relapsed APL without employing laboratory monitor-
ing of arsenic trioxide levels during the induction, con-
solidation and maintenance phases of treatment in
relapsed APL.Case presentation
A 33-year-old Caucasian man presented to an outside
hospital 6 years ago with pancytopenia. Comorbid condi-
tions consisted of human immunodeficiency virus infec-
tion diagnosed 19 years ago and treated with highly active
antiretroviral therapy, and an 8-year history of chronic
kidney disease secondary to focal segmental glomerulo-
sclerosis and congenital solitary kidney. Bone marrow at
presentation was notable for 75% involvement with abnor-
mal promyelocytes. Fluorescence in-situ hybridization
studies and reverse transcriptase-polymerase chain reac-
tion (RT-PCR) confirmed the t(15;17) translocation and
presence of the promyelocytic leukemia (PML)-RARαal Ltd. This is an Open Access article distributed under the terms of the Creative
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Induction therapy consisted of daunorubicin 45mg/m2 daily
on days 1 through to 3 with cytarabine 100mg/m2 daily on
days 1 through to 7 concurrent with all-trans retinoic
acid (ATRA) 40mg/m2 administered twice daily. Two
cycles of consolidation daunorubicin 45mg/m2 daily on
days 1 through to 3 were subsequently administered
followed by 4 months of maintenance ATRA therapy;
ATRA was discontinued prematurely due to near
lethal pancreatitis in the setting of marked hypertri-
glyceridemia associated with the drug. He achieved
and remained in remission, confirmed by repeated
RT-PCR, for 3 years.
He presented subsequently to our hospital with neu-
tropenic fever, pancytopenia, and low-grade dissemi-
nated intravascular coagulation. Bone marrow aspiration
demonstrated relapsed APL with 80 to 90% cellularity
and promyelocytes compromising 66% of the differential
leukocyte count, as well as the t(15;17)(q22;q12) trans-
location and PML-RARα fusion transcript.
Given the patient’s history of severe pancreatitis
related to ATRA, induction consisted of single agent
arsenic trioxide 0.1mg/kg IV every other day while re-
ceiving hemodialysis (commenced 6 months prior to
the diagnosis of his relapse) four times weekly.
Complete blood counts, sodium, potassium, chloride,
bicarbonate, blood urea nitrogen, creatinine, glucose
prothrombin time, activated prothrombin time, and fi-
brinogen were monitored daily. The QTc duration was
monitored daily via an electrocardiogram as well as
pre- and post-dialysis on dialysis days for the first 2
weeks of induction. Given an observed stability of the
QTc, electrocardiograms were then monitored weekly.
Magnesium and potassium levels were maintained
above 2.0mEq/L and 4.0mmol/L respectively. Aspartate
aminotransferase and alanine aminotransferase levels
were monitored weekly. Following 60 days of induc-
tion, a persistently elevated PML-RARα fusion tran-
script was detected on RT-PCR. The dose of arsenic
trioxide was then increased to 0.15mg/kg every other
day and continued for an additional 60 days. During
this interval the patient required a brief hospital stay
and arsenic trioxide dose interruption for hypergly-
cemia, which was determined to be adult-onset insu-
lin-dependent diabetes probably exacerbated by arsenic
trioxide therapy. A bone marrow biopsy after the sec-
ond 60-day period confirmed remission. Consolidation
consisted of single agent idarubicin at 12mg/m2 on
days 1 and 2 every 28 days for two cycles. Mainten-
ance consisted of 27 doses of arsenic trioxide. Treat-
ment commenced with 0.1mg/kg arsenic trioxide
Monday, Wednesday, and Friday; excessive fatigue after
nine doses prompted the remaining doses to be delivered
on a Tuesday and Friday schedule.The patient has moved from the area but remains
alive and free of relapse at the time of this writing.
Given his comorbidities, the patient was not felt to be a
candidate for high-dose chemotherapy with stem cell
support.
Discussion
There is a paucity of literature involving treatment of
relapsed APL in the setting of advanced renal failure re-
quiring dialysis and the need for surveillance of arsenic
levels during the treatment process. Two cases involving
the successful usage of arsenic trioxide in dialysis-
dependent patients have been published to date: one in-
volving a patient receiving hemodialysis thrice weekly
whereas the other received arsenic trioxide in the setting
of continuous ambulatory peritoneal dialysis; both
employed serum arsenic levels [6,7].
Arsenic trioxide is rapidly cleared from blood; yet,
only a small fraction of the daily drug dose under-
goes urinary excretion, making therapy in patients
with impaired renal function potentially challenging.
The majority of the agent is sequestered in bodily tis-
sues and undergoes delayed elimination over many
weeks to months [8,9], suggesting that excess accu-
mulation in the serum of patients with impaired renal
function is unlikely. Readily available assays measure
only elemental arsenic, and although newer and more
sensitive assays appropriately measure organic arsen-
ical compounds, these are not accessible in a timely
fashion. Dialysis-induced compartmental shifts further
limit the value of accurate measurement of arsenic
trioxide; in the treatment of toxic arsenic ingestion,
post-dialysis levels may actually exceed pre-dialysis
levels [10,11].
In non-dialysis-dependent patients, arsenic trioxide
has demonstrated efficacy during induction employing
both fixed daily dosing (10mg or 15mg daily) and
weight-based dosing (0.06–0.20mg/kg/day) [2-5]. We
adopted a ‘go low, go slow’ approach in the treatment of
our patient, beginning with 0.1mg/kg arsenic trioxide
every other day while monitoring for common side
effects including: QTc prolongation, hepatic dysfunction,
fluid retention, electrolyte imbalances, cytopenias and
constitutional changes. As arsenic trioxide concentra-
tions were not assessed or monitored, the titration of ar-
senic trioxide was based on toxicity profile. Based on the
pharmacodynamics noted above, we suspected that re-
sidual arsenic, having accumulated in various bodily
tissues, would continue to provide efficacy long after our
patient’s last dosing. Consequently, consolidation con-
sisted of single agent idarubicin followed by maintenance
arsenic trioxide. Surveillance for the PML-RARα fusion
transcript via RT-PCR continues to suggest remission at
the time of this writing.
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Arsenic trioxide can be used safely and effectively to
treat APL in patients with advanced renal failure. Given
the difficulty in obtaining accurate serum levels of
arsenic trioxide and the relative ease of monitoring for
common treatment-related side effects, we suggest fore-
going monitoring of arsenic trioxide levels during treat-
ment of relapsed APL in dialysis-dependent patients.
Combining a low initial dose with slow dose escalation
with vigilant monitoring for common side effects pro-
vides an effective and efficient means of administering
arsenic trioxide therapy.
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